2021 International Congress of Diabetes and Metabolism

S1 Clinical diabetes and therapeutics 1 : Diabetes and COVID-19 LIVE Channel A	16:30~18:30 / Thursday 7 October Chairman:Seok Won Park, Daisuke Yabe
Although optimal management of dyslipidemia is very important to reduce the risk for cardiovascular disease in patients with diabetes, several controversies still exist in this area. In this session, four speakers with extensive experience in the field of dyslipidemia will address the most pertinent controversies in lipid management and deliver the current evidence. In addition, the Korean CVD related data will be discussed. This session will provide further insights in management of dyslipidemia.
Soo Lim Seoul National University, Korea	S1-1Diabetes and COVID-19: general introduction
Andrea Luk The Chinese University of Hong Kong, China	S1-2Diabetes and infection and COVID-19
Mitsuru Ohsugi National Center for Global Health and Medicine, Japan	S1-3Diabetes and COVID-19: Japanese perspectives
Szu-Min Hsieh National Taiwan University Hospital, Taiwan	S1-4Covid-19 vaccine development in Taiwan

S5 Clinical diabetes and therapeutics 2 :
From insulin to up-to-date agents LIVE Channel A

09:00~11:00 / Friday 8 October
Chairman:Hak Chul Jang, Sung Rae Kim

Overview

After the discovery of insulin in 1921, diabetes therapeutics with various mechanisms have evolved for the management of hyperglycemia in patients with diabetes. This session titled, ��From insulin to up-to-date agents', is a clinical session that is intended to celebrate the 100th anniversary of insulin's discovery and the new era of diabetes therapeutics - SGLT 2 inhibitors and incretin therapy. This session will provide the latest knowledge and insights for clinicians for type-2 diabetes.

Kun-Ho Yoon: The Catholic University of Korea, Korea

S5-1From insulin to up-to-date agents

Silvio Inzucchi: Yale School of Medicine, USA

S5-2Treating diabetes in the patient with a history of stroke

Hyuk-Sang Kwon: The Catholic University of Korea, Korea

S5-3Benefit of SGLT2i across the cardiorenal continuum

Young Min Cho: Seoul National University, Korea

S5-4Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists

Panel discussion

Jayoung Jeon (Ajou University, Korea)

Bo Yeon Kim (Soonchunhyang University, Korea)

Tae Nyun Kim (Inje University, Korea)

S9 Clinical diabetes and therapeutics 3 :
Up to date of diabetes management LIVE Channel A

13:20~15:20 / Friday 8 October
Chairman:Sei Hyun Baik, Yeon Ah Sung

Overview

The paradigm of diabetes management is shifting to a wider spectrum across all ages with more efficacy and safety. In this session, new concepts will be introduced for pharmacological treatment in pediatric type 2 diabetes. Long journey for type 1 diabetes in adults will be discussed, focusing on management. The GLP1/GIP combination therapy shows a new, ground-breaking incretin therapy in diabetes with a reduction in related complications. This session will provide new insights into diabetes management.

Pietro Galassetti: AstraZeneca, USA

S9-1Pediatric type 2 diabetes: a very different picture compared to adult disease

Jae Hyeon Kim: Sungkyunkwan University, Korea

S9-2Management of type 1 diabetes in adults: 2021 update

Michael A. Nauck: Ruhr-University, Germany

S9-3Next chapter in incretin-based therapies: dual GIP/GLP-1 receptor agonists

Panel discussion

Jun Hwa Hong (Eulji University, Korea)

Dong Won YI (Pusan National University, Korea)

Jin Hwa Kim (Chosun University, Korea)

S13 Clinical diabetes and therapeutics 4 :
Diabetes technology LIVE Channel A

09:00~11:00 / Saturday 9 October
Chairman:Kyoil Suh, Eun Gyoung Hong

Overview

New information technology has been applied for the treatment and management of diabetes. In this session, we will introduce a model for predicting the outcome of diabetes using fundus images, utilizing an artificial intelligence system and introduce a more developed closed-loop insulin delivery device. In addition, we would like to introduce a national project in Korea that utilizes various communication technologies to educate diabetic patients more efficiently in primary clinics across the country. This session may suggest a new path to the management of diabetes.

Jae-Seung Yun: The Catholic University of Korea, Korea

S13-1Application of AI to screening and management of type 2 diabetes

Jae Hyoung Cho: The Catholic University of Korea, Korea

S13-2Korean national pilot project using information technology for diabetes education in private clinics

Sang-Man Jin: Sungkyunkwan University, Korea

S13-3Advanced hybrid closed-loop (AHCL) devices: are we ready?

Panel discussion

Jin Ook Chung (Chonnam National University, Korea)

Bu Kyung Kim (Kosin University, Korea)

Sangmo Hong (Hanyang University, Korea)

S17 Clinical diabetes and therapeutics 5 : Novel anti-diabetes therapeutics LIVE Channel A	14:30~16:30 / Saturday 9 October Chairman:Soon Jib Yoo, Kyung Mook Choi, Kathryn Tan
Although optimal management of dyslipidemia is very important to reduce the risk for cardiovascular disease in patients with diabetes, several controversies still exist in this area. In this session, four speakers with extensive experience in the field of dyslipidemia will address the most pertinent controversies in lipid management and deliver the current evidence. In addition, the Korean CVD related data will be discussed. This session will provide further insights in management of dyslipidemia.
Kohjiro Ueki National Center for Global Health and Medicine, Japan	S17-1Imeglimin: its mode of action and clinical perspectives
Wayne H.H. Sheu Taipei Veterans General Hospital, Taiwan	S17-2GLP-1 RA in Asian population
Shizuka Kaneko Takatsuki Red Cross Hospital, Japan	S17-3GIP/GLP-1 dual agonist from an Asian perspective
Elaine Chow The Univerisity of Hong Kong, China	S17-4How should we integrate new technologies in diabetes care?

Main symposia